Today in Medmultilingua
Neuralink’s brain-computer interface is moving from science fiction into early clinical reality. A Canadian ALS patient has received the company’s N1 implant as part of the CAN-PRIME trial, a study designed to evaluate whether signals from the brain can help people with paralysis or ALS control computers and smartphones through intended movement. For patients who may lose speech and mobility while remaining mentally alert, this technology could open a new path to communication, independence, and digital access. Still, these advances remain experimental and must be measured carefully for safety, reliability, privacy, accessibility, and real impact on quality of life.





